Prothena | PRTA - Cost Of Sales

Stock Price
8.65
Daily Change
0.01 0.12%
Monthly
-5.36%
Yearly
-45.29%
Q1 Forecast
8.74

Prothena reported $28.94M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Exelixis USD 26.48M 7.91M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
MacroGenics USD 44.3M 5.4M Sep/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xoma 116K 112.7K Jun/2024